Novel nitrogen-containing aromatic heterocyclic compound

US2018312503A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2018312503-A1
Application numberUS-201615769844-A
CountryUS
Kind codeA1
Filing dateOct 21, 2016
Priority dateOct 23, 2015
Publication dateNov 1, 2018
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A compound represented by general formula [I] wherein X represents N or the like, Y represents CH or the like; R A represents a cycloalkyl group which may be substituted or the like, R 1 represents an alkyl group or the like, R 2 represents an alkyl group which may be substituted or the like, R 3 represents a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof has an inhibitory activity on aldosterone synthetase, and is useful as a prophylactic and/or therapeutic agent for various diseases or symptoms associated with aldosterone.

First claim

Opening claim text (preview).

1 . A compound of the following formula [I]: wherein X and Y represent any of the following (1) to (3): (1) X is N, and Y is CH or C—R Y , (2) X is CH, and Y is N, or (3) X is CH, and Y is CH; R Y represents an alkyl group; R A represents a cycloalkyl group which may be substituted, a cycloalkenyl group which may be substituted, an aryl group which may be substituted, or a 6- to 10-membered monocyclic or bicyclic heteroaryl group which may be partially hydrogenated and may be substituted; R 1 represents a hydrogen atom, or an alkyl group; R 2 represents an alkyl group which may be substituted, a cycloalkyl group which may be substituted, an aliphatic heterocyclic group which may be substituted, or a heteroaryl group which may be partially hydrogenated and may be substituted; and R 3 represents a hydrogen atom, or an alkyl group, or a pharmaceutically acceptable salt thereof. 2 . The compound according to claim 1 , wherein substituents of the cycloalkyl group which may be substituted, the cycloalkenyl group which may be substituted, the aryl group which may be substituted, and the 6- to 10-membered monocyclic or bicyclic heteroaryl group which may be partially hydrogenated and may be substituted, represented by R A , are 1-3 groups each independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxyalkyl group, and an alkoxy group, in the aryl group which may be substituted, represented by R A , the aryl moiety is a 6- to 10-membered monocyclic or bicyclic aryl, in the 6- to 10-membered heteroaryl group which may be partially hydrogenated and may be substituted, represented by R A , the heteroaryl moiety is a 6- to 10 membered heteroaryl group containing 1-2 heteroatoms independently selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom; a substituent of (i) the alkyl group which may be substituted, represented by R 2 , is 1-3 groups each independently selected from the group consisting of a halogen atom; a hydroxyl group; an oxo group; a carbamoyl group which may be substituted with 1-2 alkyl groups; an alkylsulfonyl group; an alkoxy group which may be substituted with a carbamoyl group which may be substituted with 1-2 alkyl groups; an aliphatic heterocyclic group which may be substituted with 1-3 groups independently selected from the group consisting of a hydroxyl group, an oxo group, an alkyl group, an alkylsulfonyl group, and an alkoxycarbonyl group; an alkoxycarbonyl group; an amino group which may be substituted with 1-2 groups independently selected from an alkyl group and an alkanoyl group; and a heteroaryl group, substituents of (ii) the cycloalkyl group which may be substituted, (iii) the aliphatic heterocyclic group which may be substituted, and (iv) the heteroaryl group which may be partially hydrogenated and may be substituted are 1-3 groups each independently selected from the group consisting of a halogen atom; a hydroxyl group; an oxo group; an alkyl group which may be substituted with 1-3 groups independently selected from the group consisting of a carbamoyl group which may be substituted with 1-2 alkyl groups, a hydroxyl group, and an alkylsulfonyl group; an alkoxy group which may be substituted with a carbamoyl group which may be substituted with 1-2 alkyl groups; an aliphatic heterocyclic group which may be substituted with 1-3 groups independently selected from the group consisting of a hydroxyl group, an oxo group, an alkyl group, an alkylsulfonyl group, and an alkoxycarbonyl group; an alkoxycarbonyl group; an amino group which may be substituted with 1-2 groups independently selected from the group consisting of an alkyl group and an alkanoyl group; and a heteroaryl group, in the respective substituents of the above (i) to (iv), the aliphatic heterocyclic group is a 4- to 9-membered monocyclic or bicyclic aliphatic heterocyclic group containing 1 to 2 heteroatoms independently selected from a sulfur atom, an oxygen atom, or a nitrogen atom, in the respective substituents of the above (i) to (iv), the heteroaryl group is a 5- to 10-membered monocyclic or bicyclic heteroaryl group containing 1 to 4 heteroatoms independently selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom, in the aliphatic heterocyclic group which may be substituted, represented by R 2 , the heterocyclic moiety is a 4- to 9-membered monocyclic or bicyclic aliphatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom; and in the heteroaryl group which may be partially hydrogenated and may be substituted, represented by R 2 , the heteroaryl moiety is a 5- to 10-membered monocyclic or bicyclic heteroaryl, or a pharmaceutically acceptable salt thereof. 3 . The compound according to claim 1 or 2 , wherein substituents of the cycloalkyl group which may be substituted, the cycloalkenyl group which may be substituted, the aryl group which may be substituted, and the 6- to 10-membered monocyclic or bicyclic heteroaryl group which may be partially hydrogenated and may be substituted, represented by R A , are 1-3 groups each independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxyalkyl group, and an alkoxy group, in the aryl group which may be substituted, represented by R A , the aryl moiety is phenyl or naphthyl, in the 6- to 10-membered heteroaryl group which may be partially hydrogenated and may be substituted, represented by R A , the heteroaryl moiety is pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazinyl, triazinyl, indolyl, isoindolyl, indazolyl, benzimidazolyl, benzothiazolyl, benzofuranyl, quinolyl, isoquinolyl, imidazopyridyl, or benzopyranyl; a substituent of (i) the alkyl group which may be substituted, represented by R 2 , is 1-3 groups independently selected from the group consisting of a halogen atom; a hydroxyl group; an oxo group; a carbamoyl group which may be substituted with 1-2 alkyl groups; an alkylsulfonyl group; an alkoxy group which may be substituted with a carbamoyl group which may be substituted with 1-2 alkyl groups; an aliphatic heterocyclic group which may be substituted with 1-3 groups independently selected from the group consisting of a hydroxyl group, an oxo group, an alkyl group, an alkylsulfonyl group, and an alkoxycarbonyl group; an alkoxycarbonyl group; an amino group which may be substituted with 1-2 groups independently selected from the group consisting of an alkyl group and an alkanoyl group; and a heteroaryl group, substituents of (ii) the cycloalkyl group which may be substituted, (iii) the aliphatic heterocyclic group which may be substituted, and (iv) the heteroaryl group which may be partially hydrogenated and may be substituted, represented by R 2 , are 1-3 groups each independently selected from the group consisting of a halogen atom; a hydroxyl group; an oxo group; an alkyl group which may be substituted with 1-3 groups independently selected from the group consisting of a hydroxyl group, a carbamoyl group which may be substituted with 1-2 alkyl groups, and an alkylsulfonyl group; an alkoxy group which may be substituted with a carbamoyl group which may be substituted with 1-2 alkyl groups; an aliphatic heterocyclic group which may be substituted with 1-3 groups independently selected from the group consisting of a hydroxyl group, an oxo group, an alkyl group, an alkylsulfonyl group, and alkoxycarbonyl group; an alkoxycarbonyl group; an amino group which may be substituted with 1-2 groups independently selected from t

Assignees

Inventors

Classifications

  • Antihypertensives · CPC title

  • containing three or more hetero rings · CPC title

  • linked by a chain containing hetero atoms as chain links · CPC title

  • C07D471/04Primary

    Ortho-condensed systems · CPC title

  • with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2018312503A1 cover?
A compound represented by general formula [I] wherein X represents N or the like, Y represents CH or the like; R A represents a cycloalkyl group which may be substituted or the like, R 1 represents an alkyl group or the like, R 2 represents an alkyl group which may be substituted or the like, R 3 represents a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof has…
Who is the assignee on this patent?
Mitsubishi Tanabe Pharma Corp
What technology area does this patent fall under?
Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Nov 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).